Biophysical Mapping of the Adenosine A2A Receptor

A new approach to generating information on ligand receptor interactions within the binding pocket of G protein-coupled receptors has been developed, called Biophysical Mapping (BPM). Starting from a stabilized receptor (StaR), minimally engineered for thermostability, additional single mutations are then added at positions that could be involved in small molecule interactions. The StaR and a panel of binding site mutants are captured onto Biacore chips to enable characterization of the binding of small molecule ligands using surface plasmon resonance (SPR) measurement. A matrix of binding data for a set of ligands versus each active site mutation is then generated, providing specific affinity and kinetic information (KD, kon, and koff) of receptor–ligand interactions. This data set, in combination with molecular modeling and docking, is used to map the small molecule binding site for each class of compounds. Taken together, the many constraints provided by these data identify key protein–ligand interactions and allow the shape of the site to be refined to produce a high quality three-dimensional picture of ligand binding, thereby facilitating structure based drug design. Results of biophysical mapping of the adenosine A2A receptor are presented.

[1]  F. Lichtenberger,et al.  Abbreviations Used , 1979, Confronting the Bomb.

[2]  M. Burghammer,et al.  Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.

[3]  G. Marucci,et al.  Adenosine receptor modeling: what does the A2A crystal structure tell us? , 2010, Current topics in medicinal chemistry.

[4]  J. Salamone.  Preladenant, a novel adenosine A(2A) receptor antagonist for the potential treatment of parkinsonism and other disorders. , 2010, IDrugs : the investigational drugs journal.

[5]  Yoko Shibata,et al.  Co-evolving stability and conformational homogeneity of the human adenosine A2a receptor , 2008, Proceedings of the National Academy of Sciences.

[6]  R. Hodgson,et al.  Recent progress in the discovery of adenosine A(2A) receptor antagonists for the treatment of Parkinson's disease. , 2010, Current opinion in drug discovery & development.

[7]  Prashant V Desai,et al.  Homology modeling of G-protein-coupled receptors and implications in drug design. , 2006, Current medicinal chemistry.

[8]  Jonathan A. Javitch,et al.  Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist , 2010, Science.

[9]  Frank E. Blaney,et al.  4.26 – Seven Transmembrane G Protein-Coupled Receptors: Insights for Drug Design from Structure and Modeling , 2007 .

[10]  Gebhard F. X. Schertler,et al.  Structure of a β1-adrenergic G-protein-coupled receptor , 2008, Nature.

[11]  Ruben Abagyan,et al.  GPCR 3D homology models for ligand screening: Lessons learned from blind predictions of adenosine A2a receptor complex , 2010, Proteins.

[12]  F. Pedata,et al.  Adenosine A2A receptors and brain injury: Broad spectrum of neuroprotection, multifaceted actions and “fine tuning” modulation , 2007, Progress in Neurobiology.

[13]  Kenneth A Jacobson,et al.  Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists. , 2003, Journal of medicinal chemistry.

[14]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[15]  Yoko Shibata,et al.  Thermostabilisation of the neurotensin receptor NTS1 , 2009, Journal of molecular biology.

[16]  Yoko Shibata,et al.  Conformational thermostabilization of the β1-adrenergic receptor in a detergent-resistant form , 2008, Proceedings of the National Academy of Sciences.

[17]  Dov Barak,et al.  Evaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure. , 2009, Journal of medicinal chemistry.

[18]  Nathan Robertson,et al.  The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery , 2011, Neuropharmacology.

[19]  G. Spalluto,et al.  7-Substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility. , 2002, Journal of medicinal chemistry.

[20]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[21]  P. Jenner.  Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson’s disease , 2005, Expert opinion on investigational drugs.

[22]  F. Blaney,et al.  GPCR Homology Model Development and Application , 2010 .

[23]  B. Neustadt,et al.  Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines. , 2007, Bioorganic & medicinal chemistry letters.

[24]  R. Stevens,et al.  High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.

[25]  Krzysztof Palczewski,et al.  Sequence analyses of G-protein-coupled receptors: similarities to rhodopsin. , 2003, Biochemistry.

[26]  W. Goddard,et al.  Computational modeling of structure-function of g protein-coupled receptors with applications for drug design. , 2010, Current medicinal chemistry.

[27]  R. Stevens,et al.  Structure of an Agonist-Bound Human A2A Adenosine Receptor , 2011, Science.

[28]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[29]  R. Stevens,et al.  The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.

[30]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[31]  Gregg Siegal,et al.  Fragment screening of stabilized G-protein-coupled receptors using biophysical methods. , 2011, Methods in enzymology.

[32]  R. Abagyan,et al.  GPCR 3 D homology models for ligand screening : Lessons learned from blind predictions of adenosine A 2 a receptor complex , 2009 .

[33]  J. Daly.  Alkylxanthines as research tools. , 2000, Journal of the autonomic nervous system.

[34]  C. Müller,et al.  Multigram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease. , 2004, The Journal of organic chemistry.

[35]  K. Fuxe,et al.  Kinetic and functional properties of [3H]ZM241385, a high affinity antagonist for adenosine A2A receptors. , 2005, Life sciences.

[36]  Feixiong Cheng,et al.  Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. , 2010, European journal of medicinal chemistry.

[37]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[38]  A. IJzerman,et al.  Potent antagonists for the human adenosine A2B receptor. Derivatives of the triazolotriazine adenosine receptor antagonist ZM241385 with high affinity , 1999 .

[39]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[40]  K. Jacobson,et al.  [3H]xanthine amine congener of 1,3-dipropyl-8-phenylxanthine: an antagonist radioligand for adenosine receptors. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R. Abagyan,et al.  Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.

[42]  A Sali,et al.  Comparative protein modeling by satisfaction of spatial restraints. , 1996, Molecular medicine today.

[43]  Vsevolod Katritch,et al.  Ligand binding and subtype selectivity of the human A(2A) adenosine receptor: identification and characterization of essential amino acid residues. , 2010, The Journal of biological chemistry.

[44]  M. Congreve,et al.  Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine. , 2011, Structure.